CTOs on the Move

resTORbio

www.restorbio.com

 
resTORbio, Inc. is a clinical stage company, developing medicines to treat aging-related diseases and conditions. resTORbio`s lead program targets the mechanistic target of rapamycin complex 1 (mTORC1) pathway to treat aging-related diseases and conditions. Initially, resTORbio is focused on developing medicines that address conditions caused by immunosenescence, the decline in immune function due to aging. resTORbio has initiated a Phase 2b trial for its lead product candidate, RTB101, evaluating its potential to reduce the incidence of respiratory tract infections (RTI) in elderly individuals at increased risk of RTI-related morbidity and mortality. resTORbio`s lead program is built upon two Phase ...
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.restorbio.com
  • 501 Boylston Street Suite 6102
    Boston, MA USA 02116
  • Phone: 617.482.2333

Executives

Name Title Contact Details

Funding

resTORbio raised $40M on 11/30/2017

Similar Companies

Hinsdale Hematology-Oncology Associates

Hinsdale Hematology-Oncology Associates is a Hinsdale, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ReviveRX

ReviveRX is a leading licensed mail-order pharmacy specializing in generic and compounded medications. Our compounds are expertly crafted in USP-certified clean rooms at our Houston headquarters, ensuring the highest quality standards. We work closely with best-in-class pharmacists, scientists, healthcare providers, and pharmaceutical manufacturers to provide high-quality, dependable products to our patients and clinic partners.

OncoResponse

OncoResponse Inc., a privately held immuno-oncology company, has partnered with MD Anderson Cancer Center (MDACC) to deploy a unique and transformational approach to the discovery of cancer therapeutics.

Locus Biosciences

Locus Biosciences` novel approach to precision antimicrobials works by taking advantage of an immune system present in many bacteria called the CRISPR-Cas system. The CRISPR-Cas system protects bacteria from invaders such as viruses by creating a small strand of RNA called a CRISPR RNA, which matches a DNA sequence specific to a given invader. If the CRISPR RNA is matched to a complementary DNA sequence, the Cas proteins will cleave the invading DNA.

Matthew Gibbs

CipherBio@SVB: Search life science fundraising news and data to discover innovative companies backed by venture investors https://t.co/mmTCuwa0Mc